Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Plain Language Summary added to the Study Details page. The update also lists recent change dates (2026-02-17, 2026-02, 2026-02-19) alongside the new content.
    Difference
    0.1%
    Check dated 2026-02-21T11:04:49.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The page shows a revision update from v3.4.1 to v3.4.2; this is a minor metadata update with no user-facing impact. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-14T08:57:31.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision: v3.4.1 was added in place of v3.4.0. No other changes to page content are visible. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-07T05:51:31.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    Adds a Show glossary option and a new revision label (v3.4.0) to the page, and normalizes capitalization for FEAR Act-related text. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-24T01:32:53.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    Revision tag updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-17T01:27:04.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    The Locations section has been expanded to include many new sites across the US, Australia, Canada, and numerous other countries, replacing the previous shorter list. This broadens geographic availability of trial sites.
    Difference
    4%
    Check dated 2025-12-19T12:55:43.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.